Copyright 2026 All rights reserved.

Business area

bHLBIO develops the innovative drug for the healthy human life, using our novel CUPID platform
which can monitor in real time the Protein-Protein Interaction (PPI) in living cell.

KRAS-BRAF

2 HITS (HIT 1 & 2) Selected

KRAS BRAF Note
FDA-DR #1

FDA-DR1

FDA-DR #2 FDA-DR2

Selected commerical library screening
(5.7k of 300k)

We have discovered 4 hit compounds
(Hit 3, 4, 5, 6)

using commercial library, and
further validation was proceed using
Hit #3 & #4 and their derivatives


Commercial library (300,000 compounds)
Selected (26,000 compounds)
Secured (5,700 compounds)
CUPID Screening (4 HITS)


  • We have discovered 4 hit compounds
    (Hit - 3, 4, 5, 6)
  • Using commercial library, and further validation was proceed using
    Hit #3 & #4 and their derivatives

Of them, we selected Hit #4-5 as a Lead (BHL-101)

and performing further validation in vitro / in vivo




BHL-101 showed better anti-proliferation activity and lower toxicity than Boehringer Ingelheim’s BI-3406

Cancer cell proliferation
Cytotoxicity




BHL-101 showed the phosphorylation inhibition activity against ERK of RAS pathway in dose-dependent manner

ERK phosphorylation test in RAS pathway